Table 2.
Characteristics of MDRO/XDRO-infected patients.
| Parameter | Number (%) or Median [IQR] |
|---|---|
| Patients with infectious syndromes | 10 |
| Colonisation | 3 (30) |
| Rectal swab positive | 2 (20) (K. pneumoniae) |
| Nasal swab positive | 1 (10) (MRSA) |
| Patients with colonisation who developed infection with the same pathogen | 1 (10) |
| Patients with >1 pathogen | 4 (40) |
| Total infectious syndromes | 18 |
| Types of infectious syndromes | |
| Pneumonia | 9 (50) |
| Hospital-acquired pneumonia | 7 (77.8) |
| Community-acquired pneumonia | 1 (11.1) |
| Unknown | 1 (11.1) |
| Complicated urinary tract infection | 4 (22.2) |
| Bloodstream infection | 2 (11.1) |
| Skin and soft tissue infection | 3 (16.7) |
| Days from hospital entry to first isolation | 24 [1–40] |
| Pathogens Acinetobacter baumannii Pseudomonas aeruginosa Klebsiella pneumoniae Proteus mirabilis Staphylococcus aureus |
Total 14 pathogens 4 (28.6) 4 (28.6) 3 (21.4) 1 (7.1) 2 (14.3) |
| Eradication of infectious syndromes Yes/No/Missing data |
7 (38.9)/8 (44.4)/3 (16.7) |
| Antibiotic | |
| Cefiderocol | 2 (20) |
| Gentamicin | 2 (20) |
| Ceftriaxone | 3 (30) |
| Meropenem | 1 (10) |
| Teicoplanin | 2 (20) |
| Colisitin i.v | 1 (10) |
| Colistin nebulised | 2 (20) |
| Tigecycline | 2 (20) |
| Ampicillin/Sulbactam | 1 (10) |
| Piperacillin/Tazobactam | 1 (10) |
| Linezolid | 1 (10) |
| Ceftobiprole | 1 (10) |
| Duration of therapy | 12 [7–21] |